BioSpectrum Asia Awards 2022 | 21 November 2022 | News
BioSpectrum Asia announces Editor’s Choice Award Winners for 2022
To appreciate the Asian companies and individuals, involved in the life sciences industry, for their commendab...Read more
China | 21 November 2022 | News
World's first atlas of airborne microbes for public health research
The microbial population of the air that surrounds us is comparatively unknown, but a research expedition led ...Read more
Europe | 25 November 2022 | News
Shionogi opens new European headquarters in Amsterdam
Shionogi has officially opened the doors to its new European headquarters in Herengracht, Amsterdam, marking t...Read more
Japan | 24 November 2022 | News
GARDP and Sumitomo Pharma announce partnership in search for new antibiotics
The Global Antibiotic Research and Development Partnership (GARDP) and Japanese firm Sumitomo Pharma Co. have ...Read more
India | 22 November 2022 | News
West introduces gamma irradiated flip-off seals in India, Asia Pacific markets
West Pharmaceutical Services, Inc. has recently expanded its seal offerings by launching Gamma Irradiated...Read more
China | 28 November 2022 | News
Hong Kong develops multifunctional nanoparticle for diagnosis & treatment of glioma
A Hong Kong Baptist University (HKBU) collaborative research team, along with researchers at Hong Kong Po...Read more
Australia | 17 November 2022 | News
Australia offers new nasal vaccine strategy to improve COVID-19 protection
Researchers from the Centenary Institute and the University of Sydney in Australia have developed a new nasal ...Read more
Korea | 14 November 2022 | News
Lemonex, IVI exchange MoU on joint vaccine development in Korea
The International Vaccine Institute (IVI), in South Korea, has signed a memorandum of understanding (MOU) with...Read more
Australia | 09 November 2022 | News
Australia announces world first regulatory approval for donor derived microbiome drug
Australian startup BiomeBank has announced the first regulatory approval for a donor derived microbiome drug p...Read more
Korea | 24 November 2022 | News
Lunit accelerates AI-powered medical imaging across major overseas channels
South Korea-based startup Lunit has signed a global distribution agreement with Indian firm CARPL.ai, an end-t...Read more
Australia | 18 November 2022 | News
Australia picks Lunit's AI-based solution for breast cancer screening
South Korea-based startup Lunit has signed a contract to supply its artificial intelligence (AI) solution for ...Read more
Japan | 17 November 2022 | News
Japan commercialises world's first test for early-stage pancreatic cancer
Hirotsu Bio Science Inc. has announced the commercialisation of "N-NOSE plus Pancreas," the first next-generat...Read more
Malaysia | 15 November 2022 | News
Boston Scientific expands operations in Malaysia
Boston Scientific Corporation, a global leader in medical device technology, has unveiled a new expansion of i...Read more
Taiwan | 16 November 2022 | News
QPS opens new preclinical research facility in Taiwan
QPS, a global contract research organisation headquartered in the US, has opened a second preclinical research...Read more
Korea | 16 November 2022 | News
Korean CRO expands partnership with Medidata to enhance clinical operations
US-based Medidata, a Dassault Systèmes company, has announced that C&R Research, the largest Korean...Read more
China | 15 November 2022 | News
WuXi establishes new vaccines CDMO facility in China
WuXi Vaccines, a leading global Contract Development and Manufacturing Organisation (CDMO), has entered into a...Read more
Invincible Diabetes Turns APAC Into Pharma Goldmine
There are over 235 million diabetic patients in Asia. China and India account for almost half of the world’s diabetic population. By 2030, without intervention, both China and India combined will have nearly half a billion diabetics. These are grim figures but for pharma firms, they represent a huge opportunity, and big pharma firms are spending billions in search of the next blockbuster drug for diabetes,according to the estimates from Singapore-based Asian Diabetes Prevention Initiative (ADPI). The diabetes care drugs market is highly fragmented in Asia Pacific (APAC) region with a few major manufacturers gaining presence in major countries of the APAC market, while the remaining market comprises other local or regionspecific manufacturers. Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as drive innovations, helping the diabetes drugs market to increase in the APAC region. Let’s look at who owns the more significant piece of the pie and the competitive landscape of diabetes treatment in the region.
For Feedback Email Us: communications@biospectrumasia.com
1 North Bridge Road,
#08-08 High Street Centre,
Singapore 179094
Email : communications@biospectrumasia.com
